Human Vaccines & Immunotherapeutics (Nov 2021)

Pityriasis rosea after administration of Pfizer-BioNTech COVID-19 vaccine

  • Olivia G. Cohen,
  • Ashley K. Clark,
  • Heather Milbar,
  • Mordechai Tarlow

DOI
https://doi.org/10.1080/21645515.2021.1963173
Journal volume & issue
Vol. 17, no. 11
pp. 4097 – 4098

Abstract

Read online

Pityriasis rosea (PR) is an acute papulosquamous cutaneous disorder that classically presents with a herald patch rapidly followed by a widespread rash along skin cleavage lines. Although the exact pathogenesis of PR is unknown, current evidence suggests that an inflammatory reaction due to a viral trigger may lead to the cutaneous manifestations. COVID-19 has been reported as one such viral trigger for PR. Previously, PR has been reported in temporal association with various viral inoculations. This article presents a case of PR in a 66-year-old black male 1 week after administration of the Pfizer-BioNTech COVID-19 vaccine.

Keywords